The
Canadian Lung Cancer Therapeutics Market is poised to experience significant
growth during the forecast period. This can be attributed to the substantial
investments in research and innovation by key industry players, coupled with
the rising demand for customized therapies for lung cancer treatment across the
region. Additionally, the increasing availability of highly effective
medications is expected to drive market growth in Canada. Furthermore, the
prevalence of unhealthy lifestyles is anticipated to create lucrative
opportunities in the Canada Lung Cancer Therapeutics Market.According to
the Canadian Cancer Society, an estimated 30,000 Canadians were diagnosed with
lung and bronchus cancer, accounting for 13% of all new cancer cases in 2022.
Moreover, 20,700 Canadians succumbed to lung and bronchus cancer, representing
24% of all cancer-related deaths in 2022.
Technological advancements
Technological
advancements have played a significant role in influencing the growth of the
Canada Lung Cancer Therapeutics Market. These advancements have revolutionized
various aspects of lung cancer diagnosis, treatment, and research, leading to
improved patient outcomes and expanded therapeutic options. Technological
advancements have enabled the development of more accurate and efficient
diagnostic tools for lung cancer. Imaging techniques, such as computed
tomography (CT) scans and positron emission tomography (PET) scans, have become
more sophisticated, allowing for earlier detection of lung tumors and improved
staging of the disease. Additionally, molecular testing and biomarker analysis
have facilitated the identification of specific genetic mutations and
alterations in lung cancer cells, aiding in personalized treatment approaches.
Technological
advancements have paved the way for precision medicine in lung cancer
treatment. Genomic profiling techniques, such as next-generation sequencing
(NGS), have become more accessible and cost-effective, enabling the
identification of actionable mutations and biomarkers in lung cancer patients.
This information guides the selection of targeted therapies, such as tyrosine
kinase inhibitors (TKIs), which specifically block the activity of mutated
genes or proteins driving tumor growth. These targeted therapies have shown
remarkable efficacy and have transformed the treatment landscape for certain
subsets of lung cancer patients.
Technological
advancements have contributed to the development of immunotherapies for lung
cancer. Immune checkpoint inhibitors, such as programmed cell death protein 1
(PD-1) and programmed death-ligand 1 (PD-L1) inhibitors, have demonstrated
significant clinical benefit by harnessing the body's immune system to fight
cancer cells. Advanced techniques for immune profiling, such as immune cell
characterization and monitoring of immune response markers, help identify
patients who are most likely to respond to immunotherapies and enable more precise
treatment selection.
Growing emphasis on personalized medicine
The
growing emphasis on personalized medicine has had a significant influence on
the growth of the Canada Lung Cancer Therapeutics Market. Personalized
medicine, also known as precision medicine, aims to tailor medical treatment to
individual patients based on their specific characteristics, such as genetic
makeup, biomarker profiles, and disease characteristics. In the context of lung
cancer, personalized medicine has led to several advancements that have
positively impacted the market's growth.
Personalized
medicine has revolutionized the treatment of lung cancer by enabling the
development of targeted therapies. Through molecular profiling and genetic
testing, specific genetic mutations and alterations in lung cancer cells can be
identified. This information helps identify patients who are most likely to
benefit from targeted therapies, such as tyrosine kinase inhibitors (TKIs),
that block the activity of mutated genes or proteins driving tumor growth. The
availability and efficacy of targeted therapies have expanded treatment
options, improved response rates, and prolonged survival for certain subsets of
lung cancer patients.
Personalized
medicine has placed significant emphasis on identifying biomarkers that predict
treatment response and patient outcomes. Genetic testing, next-generation
sequencing (NGS), and other advanced techniques have enabled the identification
of specific biomarkers in lung cancer, such as epidermal growth factor receptor
(EGFR) mutations, anaplastic lymphoma kinase (ALK) rearrangements, and
programmed death-ligand 1 (PD-L1) expression. These biomarkers help guide
treatment decisions and assist in selecting the most appropriate therapies for
individual patients. The identification and utilization of biomarkers have
resulted in improved patient selection, increased treatment efficacy, and
reduced adverse effects.
The
growing emphasis on personalized medicine has spurred significant research and
development (R&D) activities in the Canada Lung Cancer Therapeutics Market.
Academic institutions, pharmaceutical companies, and research organizations are
investing in the discovery and development of novel targeted therapies,
immunotherapies, and treatment modalities that align with personalized medicine
principles. The increased focus on personalized medicine has fueled
collaborations and partnerships between researchers, clinicians, and industry
stakeholders, driving innovation and the introduction of new therapeutic
options.
Download Free Sample Report
Increasing research and developments efforts
Increasing
research and development (R&D) efforts have a profound impact on the growth
and advancement of the Canada Lung Cancer Therapeutics Market. Research and
development activities drive innovation, foster scientific discoveries, and
contribute to the development of novel therapies, treatment strategies, and
diagnostic tools. R&D efforts in the field of lung cancer therapeutics lead
to the discovery and development of novel therapeutic agents. Researchers investigate
various molecular targets, signaling pathways, and cellular mechanisms involved
in lung cancer progression, metastasis, and drug resistance. These efforts
identify new potential targets for drug intervention, which can result in the
development of innovative drugs, such as targeted therapies, immunotherapies,
and combination therapies. The introduction of novel therapeutic agents expands
the treatment options available to patients, improves response rates, and
enhances overall patient outcomes. Increasing research and development efforts
contribute to advancements in treatment modalities for lung cancer. This
includes the development of new treatment approaches beyond traditional
chemotherapy and radiation therapy. For example, advancements in minimally
invasive surgical techniques, such as video-assisted thoracic surgery (VATS),
allow for more precise and less invasive tumor resections. Additionally,
research in areas such as radiotherapy, stereotactic body radiation therapy
(SBRT), and radiofrequency ablation (RFA) has improved the delivery and
effectiveness of radiation-based treatments. These advancements enhance the
overall treatment landscape and provide more options for lung cancer patients. Increasing
research and development efforts contribute to the identification and
understanding of biomarkers associated with lung cancer. Through extensive
molecular profiling and genetic analysis, researchers identify specific genetic
mutations, biomarkers, and other molecular characteristics that influence tumor
behavior and treatment response. This knowledge enables personalized medicine
approaches, guiding treatment decisions based on the unique genetic profile of
each patient. Biomarker identification facilitates the selection of targeted
therapies and immunotherapies, improving treatment efficacy and reducing
unnecessary side effects.
Supportive regulatory environment
A
supportive regulatory environment plays a crucial role in influencing the
growth of the Canada Lung Cancer Therapeutics Market. Regulatory agencies and
policies provide guidelines, standards, and oversight to ensure the safety,
efficacy, and accessibility of lung cancer therapeutics. Regulatory agencies,
such as Health Canada, may offer expedited approval pathways and fast-track
designations for promising lung cancer therapies. These programs aim to
accelerate the review and approval process for innovative treatments that
address significant unmet medical needs. By expediting the regulatory timeline,
these initiatives allow patients to access new therapies sooner, facilitating
timely treatment and improving patient outcomes. A supportive regulatory
environment provides clear and transparent guidance for conducting clinical
trials in the field of lung cancer therapeutics. Regulatory agencies establish
guidelines and requirements for trial design, patient selection, safety
monitoring, and data collection. By offering comprehensive and standardized
regulatory frameworks, these guidelines facilitate the planning and execution
of clinical trials, ensuring their quality, reliability, and ethical conduct. Regulatory
agencies foster collaboration and engagement with various stakeholders,
including industry, healthcare professionals, patient advocacy groups, and
academic institutions. This collaboration allows for the exchange of knowledge,
insights, and expertise, promoting a shared understanding of the regulatory
landscape and the evolving needs of lung cancer patients. Engaging stakeholders
in the regulatory decision-making process helps ensure that regulations are
effective, responsive, and aligned with patient-centric goals.
Collaborative efforts and partnerships
Collaborative
efforts and partnerships play a pivotal role in influencing the growth of the
Canada Lung Cancer Therapeutics Market. In a complex field like lung cancer,
collaboration brings together the collective expertise, resources, and
perspectives of various stakeholders, fostering innovation, driving research
and development, and advancing patient care. Collaboration and partnerships
facilitate the exchange of knowledge, ideas, and expertise among researchers,
clinicians, academic institutions, pharmaceutical companies, and other industry
stakeholders. By sharing insights, data, and best practices, these collaborations
enable a more comprehensive understanding of lung cancer biology, treatment
strategies, and emerging trends. This knowledge exchange accelerates scientific
discoveries, promotes evidence-based practices, and enhances the quality of
research and development efforts. Collaborative efforts foster advancements in
R&D in the field of lung cancer therapeutics. By pooling resources,
including funding, infrastructure, and technology, stakeholders can undertake
larger and more ambitious research projects. Collaborative research initiatives
can lead to the discovery of new therapeutic targets, the development of
innovative treatments, and the identification of predictive biomarkers. Such
advancements fuel the growth of the market by expanding treatment options,
improving patient outcomes, and addressing unmet medical needs. Collaborative
efforts promote the sharing and analysis of data in the field of lung cancer.
Data pooling and collaborative research initiatives enable the integration of
diverse datasets, including genomic information, clinical outcomes, treatment
responses, and real-world evidence. By analyzing large and comprehensive
datasets, researchers can identify trends, patterns, and potential correlations
that would be otherwise difficult to observe in smaller datasets. This
data-driven collaboration enhances the understanding of lung cancer, supports
evidence-based decision-making, and facilitates the development of personalized
treatment strategies.
Recent Developments
- Tagrisso is
an oral medication developed by AstraZeneca and is indicated for the
treatment of metastatic non-small cell lung cancer (NSCLC) with specific
genetic mutations called epidermal growth factor receptor (EGFR) T790M
mutations. It was approved by Health Canada in 2018.
- Keytruda is
an immunotherapy drug developed by Merck, known as a PD-1 inhibitor. It is
used for the treatment of advanced NSCLC, either as a first-line therapy
in combination with chemotherapy or as a monotherapy for patients whose
tumors express certain biomarkers. Keytruda received approval in Canada
for lung cancer indications in 2019.
- Lorbrena,
developed by Pfizer, is an oral medication indicated for the treatment of
metastatic NSCLC with ALK-positive genetic mutations, including patients who
have progressed on other ALK inhibitors. It was approved by Health Canada
in 2020.
Market Segmentation
The
Canada Lung Cancer Therapeutics Market can be segmented by cancer cell type,
treatment, end user, region, and competitive landscape. Based on the cancer
cell type, the Canada Lung Cancer Therapeutics market can be divided into
Non-small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC). Based on
treatment, the Canada Lung Cancer Therapeutics market can be segmented into
Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapy, and Other
Treatments. Based on the end user, the Canada Lung Cancer Therapeutics market
can be segmented into Hospital Pharmacies, Retail Pharmacies, Online
Pharmacies, and Others
Market Players
AstraZeneca
Canada Inc, Boehringer Ingelheim Canada Ltd, Bristol-Myers Squibb Canada Inc,
Eli Lilly Canada Inc, Hoffmann-La Roche Ltd, Merck & Co Inc, Pfizer Canada
Inc, Allergan Inc/Canada, Johnson & Johnson Inc/Canada are some of the
leading players operating in the Canada Lung Cancer Therapeutics Market.
|
Attribute
|
Details
|
|
Base
Year
|
2022
|
|
Historic
Data
|
2018 – 2021
|
|
Estimated
Year
|
2023
|
|
Forecast
Period
|
2024 – 2028
|
|
Quantitative
Units
|
Revenue in USD Million, and CAGR for 2018-2022 and 2023-2028
|
|
Report
Coverage
|
Revenue
forecast, company share, competitive landscape, growth factors, and trends
|
|
Segments
Covered
|
By Cancer
Cell Type
By Treatment
By End User
By Region
|
|
Regional
scope
|
Ontario
region; Quebec region; Alberta region; British Columbia region; Saskatchewan
and Manitoba region; Rest of Canada
|
|
Key
companies profiled
|
AstraZeneca Canada
Inc, Boehringer Ingelheim Canada Ltd, Bristol-Myers Squibb Canada Inc, Eli
Lilly Canada Inc, Hoffmann-La Roche Ltd, Merck & Co Inc, Pfizer Canada
Inc, Allergan Inc/Canada, Johnson & Johnson Inc/Canada
|
|
Customization
scope
|
10%
free report customization with purchase. Addition or alteration to country,
regional & segment scope.
|
|
Pricing
and purchase options
|
Avail customized purchase options to meet your exact research
needs. Explore purchase options
|
|
Delivery
Format
|
PDF and Excel through Email (We can also provide the editable
version of the report in PPT/Word format on special request)
|
Report
Scope:
In this
report, the Canada Lung Cancer Therapeutics market has been segmented into the following
categories, in addition to the industry trends which have also been detailed
below:
- Canada Lung Cancer Therapeutics Market, By Cancer
Cell Type:
o Non-small Cell Lung Cancer (NSCLC)
o Small Cell Lung Cancer (SCLC)
- Canada Lung Cancer Therapeutics Market, By Treatment:
o Chemotherapy
o Radiation Therapy
o Immunotherapy
o Targeted Therapy
o Other Treatments
- Canada Lung Cancer Therapeutics Market, By End
User:
o
Hospital
Pharmacies
o
Retail
Pharmacies
o
Online
Pharmacies
o
Others
- Canada Lung Cancer Therapeutics Market, By Region:
o
Ontario
o Quebec
o Alberta
o British Columbia
o Saskatchewan and Manitoba
o Rest of Canada
Competitive
Landscape
Company
Profiles: Detailed
analysis of the major companies present Canada Lung Cancer Therapeutics Market.
Available
Customizations:
With the
given market data, TechSci Research offers customizations according to a
company’s specific needs. The following customization options are available for
the report:
Company
Information
- Detailed analysis and profiling of additional market
players (up to five).
Canada Lung
Cancer Therapeutics Market is an upcoming report to be released soon. If you
wish an early delivery of this report or want to confirm the date of release,
please contact us at [email protected]